Antibody-targeted therapy: A paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma

Current Opinion in Hematology

Volumn 11, Issue 6, 2004, Pages 419-425

  Van De Loosdrecht, Arjan A ^a   Huijgens, Peter C ^a   Ossenkoppele, Gert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti CD20; Antibodies; Immunotherapy; Lymphoma

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CD20 ANTIBODY; CD23 MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CHLORAMBUCIL; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; GALIXIMAB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INTERLEUKIN 2; LUMILIXIMAB; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE SULFATE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL FUNCTION; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG SAFETY; DRUG TARGETING; FOLLOW UP; HUMAN; IMMUNOPHARMACOLOGY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD20; COMBINED MODALITY THERAPY; HUMANS; IMMUNIZATION, PASSIVE; LYMPHOMA, B-CELL;

EID: 8544234258     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000141927.77393.39     Document Type: Review

References (60)

1. Chinn P, Braslawsky G, White C, et al.: Antibody therapy of non-Hodgkin's B cell lymphoma. Cancer Immunol Immunother 2003, 52:257-280.
2. DiGaetano N, Cittera E, Nota R, et al.: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003, 171:1581-1587.
3. Manches O, Lui G, Chaperot L, et al.: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphoma. Blood 2003, 101:949-954.
4. van Sorge NM, van der Pol WL, van de Winkel JG: FcgammaR polymorphisms: implications for function disease susceptibility and immunotherapy. Tissue Antigens 2003, 61:189-202.
5. van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ: Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. Anticancer Drugs 2004, 15:189-201. This review outlines the impact of increasing insights from basic immunology on passive and active immunotherapy in leukemia and lymphoma.
6. Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
7. Teeling JL, French RR, Cragg MS, et al.: Characterisation of new CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 2004. Development of new CD20 reagents showed increased potency in CDC, which is of major importance for clinical efficacy.
8. Harris NL, Jafe ES, Diebold J, et al.: The WHO classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Arlie House, Virginia, November 1997. Histopathology 2000, 36:69-86.
9. Staudt LM: Genomic medicine: molecular diagnosis of the hematologic cancers. N Engl J Med 2003, 348:1777-1785,
10. Losses IS, Czerwinski DK, Alizadeh AA, et al.: Prediction of survival in diffuse large-B cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350:1828-1837. Six genes could be identified by quantitative real-time polymerase chain reaction analysis with strong predictive power for overall survival in DLBL independent of IPI.
11. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
12. Hennessy BT, Hanrahan EO, Daly PA: Non-Hodgkin lymphoma: an update. Lancet Oncol 2004, 5:341-353. This excellent review is of the pathogenesis and treatment of NHL based on underlying biology and healthy lymphocyte differentiation.
13. Smith MR: Rituximab: mechanisms of action and resistance. Oncogene 2003, 22:7359-7368. A comprehensive review is provided that deals with a diversity of current known resistance mechanisms of anti-CD20-targeted therapy.
14. Cesano A, Gayko U: CD22 as a target of passive immunotherapy. Semin Oncol 2003, 30:253-257.
15. Carnahan J, Wang P, Kendall R, et al.: Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003, 9:3982s-3990s. This report presents the activity of epratuzumab related to binding, signaling, and internalization of the CD22 receptor to differentiate epratuzumab clearly from other Abs to form the basis for clinical evaluation.
16. Mavromatis B, Cheson BD: Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1874-1881.
17. Leonard JP, Link BK: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody and Hu1D10 (Apolizumab). Semin Oncol 2002, 29:81-86.
18. Younes A, Hariharan K, Allen RS, et al.: Initial trials of anti-CD80 monoclonal antibody (galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Clin Lymphoma 2003, 3:257-259.
19. Tutt AL, O'Brien L, Hussain A, et al.: T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002, 168:2720-2728.
20. Vanderheide RH, Dutcher JP, Andersen JE, et al.: Phase I study of recombinant CD40 ligand in cancer patients. J Clin Oncol 2001, 19:3280-3287.
21. Moreton P, Hillmen P: Alemtuzumab therapy in B cell lymphoproliferative disorders. Semin Oncol 2003, 30:493-501.
22. Kosmos C, Stamatopoulos K, Stavroyianni N, et al.: Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 2002,16:2004-2015.
23. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
24. Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000, 18:3135-3143.
25. Colombat P, Salles G, Brousse N, et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
26. Hainsworth JD, Burris HA, Morrissey LH, et al.: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000, 95:3052-3056.
27. Hainsworth JD: Rituximab as first line maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002, 29:25-29.
28. Czuczman MS, Fallon A, Mohr A, et al.: Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002, 29:36-40.
29. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-276.
30. Marcus R, Imrie K, Belch A, et al.: An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma. Blood 2003, 102:87a.
31. Hiddemann W, Dreyling MH, Forstpointner R, et al.: Combined immunochemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma-results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003, 102:352a.
32. Zinzani PL, Pulsoni A, Perrotti A, et al.: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004, 22:2654-2661. [epub ahead of print]. The results of this randomized comparative trial show that fludarabine and mitoxantrone is superior to CHOP for front-line treatment of follicular lymphoma, and the sequential use of rituximab induces additional molecular remissions.
33. Dreyling MH, Forstpointner R, Repp R, et al.: Combined immunochemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma-final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003, 102:351a.
34. Ghielmini M, Schmilz SH, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with standard weekly X4 schedule. Blood 2004, 103:4416-4423. The benefits in terms of EFS in patients with follicular lymphoma could be significantly improved in patients responding to initial rituximab treatment by prolonged administration of four additional doses at 8-week intervals.
35. Leonard JP, Coleman M, Ketas JC, et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:3051-3059.
36. Emmanouilides C, Leonard JP, Schuster J, et al.: Multi-center, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL Blood 2003, 102:233a.
37. Dimopoulos MA, Zervas C, Zomas A, et al.: Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002, 20:2327-2333.
38. Conconi A, Martinelli G, Thieblemont C, et al.: Clinical activity of rituximab in extranodal marginal zone B cell lymphoma of MALT type. Blood 2003, 102:2741-2745.
39. Vose JM: Bexxar®: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 2004, 9:160-172.
40. Witzig TE, White CA, Gordon Ll, et al.: Safety of yttrium-90.ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:1263-1270.
41. Kamisky MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B cell non-Hodgkin's lymphoma. J Clin Oncol 2001, 19:3918-3928.
42. Wiseman GA, Gordon Ll, Multani PS, et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002, 99:4336-4342.
43. Witzig TE, Gordon Ll, Cabnillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, and transformed B cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-2463.
44. Cheson BD: Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003, 101:391-398.
45. Bennet J, Kaminsky MS, Knox SJ, et al.: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with low-grade non-Hodgkin's lymphoma treated with tositumomab and Iodine-131 tositumomab. Blood 2003, 102:91a.
46. Witzig TE, Molina A, Gordon Ll, et al.: Yttrium-90 ibritumomab tiuxetan radioimmunotherapy induces durable remissions in patents with relapsed or refractory B cell non-Hodgkin's lymphoma: analysis of long-term responders. Blood 2003, 102:1480a.
47. Davies AJ, Rohatiner AZS, Howell S, et al.: Tositumomab and iodine-131 tositumomab for recurrent indolent and transformed B cell non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:1469-1479. In this phase II study, high overall responses and CR rates were observed after a single dose of tositumomab and I-131 tositumomab in patients with recurrent indolent and transformed B-cell NHL with minor toxicities.
48. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 1997, 19:389-397.
49. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B cell lymphoma. N Engl J Med 2002, 346:235-242. This is the first randomized phase III clinical trial showing a significant increase in CR and OS in previously untreated elderly patients with aggressive NHL. This study has dramatically changed the standard treatment of aggressive NHL over the past decades and contributes to the development of innovative strategies with Ab-targeting approaches.
50. Coiffier B: Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 2004, 31:7-11.
51. Mounier N, Brier J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B cell lymphoma (DLBCL). Blood 2003, 101:4279-4284. The prognostic value of bcl-2 overexpression in DLBL could be confirmed and may be overcome by adding rituximab to standard CHOP chemotherapy.
52. Sehn LH, Donaldson J, Chhanabhai M, et al.: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. Blood 2003, 102:88a.
53. Pfreundschuh M: The Mint trial (CHOP-like regimens with or without rituximab) for young low-risk patients with diffuse large B cell non-Hodgkin's lymphoma. Early stopping after first interim analysis. Hematol J 2004, 5:593a.
54. Habermann TM, Weller EA, Morrison VA, et al.: Phase III trial of rituximab-CHOP (R-CHOP vs CHOP) with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B cell lymphoma. Blood 2003, 102:8a.
55. Pfreundschuh M, Truemper L, Kloess M, et al.: Two-weekly vs 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the combined NHL-B-2 trial of the DSHNHL. Blood 2002, 100:774a.
56. Howard O, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-1294.
57. Gianni AM, Magni M, Martelli M, et al.: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749-755. This study shows that high-dose chemotherapy with rituximab-purged autoPSCT is feasible and leads to long-term EFS and OS in the majority of patients compared with age-matched historic control subjects.
58. Arcaini L, Orlandi E, Alessandrino EP, et al.: A model of in vivo purging with rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004, 34:175-179. [epub ahead of print]. This study shows that a preparative immunochemotherapy phase before and during mobilization induces a complete B-cell depletion resulting in a lymphoma-free stem cell graft confirmed at the immunophenotypic and molecular level in patients with aggressive lymphoma.
59. Pettengell R, Linch D: Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B cell non-Hodgkin's lymphoma. Br J Haematol 2003, 12:44-48.
60. Kewalramani T, Zelenetz AD, Nimer SD, et al.: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed and primary refractory diffuse large B cell lymphoma. Blood 2004, 103:3684-3688. The addition of rituximab to ifosfamide, carboplatin, and etoposide appears to improve significantly the CR rate of patients with relapsed and primary refractory DLBL before autoPSCT, which may ultimately improve OS.